Hormonal contraception and HIV: the methods have confused the message

AIDS

Volumn 27, Issue SUIPPL.1, 2013, Pages

  Schwartz, Sheree R ^a   Pettifor, Audrey ^b   Stuart, Gretchen S ^a   Cohen, Myron S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

add injectable contraception; bias; condoms; HIV 1; hormonal contraception; pregnancy

Indexed keywords

CONTRACEPTIVE AGENT; INJECTABLE CONTRACEPTIVE AGENT;

ARTICLE; CONDOM; CONDOM USE; CONTRACEPTIVE BEHAVIOR; FEMALE; FOLLOW UP; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PREGNANCY RATE; PRIORITY JOURNAL; RISK FACTOR; UNPROTECTED SEX;

BIOMEDICAL RESEARCH; CONDOMS; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HIV INFECTIONS; HUMANS; PREGNANCY; RISK ASSESSMENT;

EID: 84885638882     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000037     Document Type: Article

References (48)

1. United Nations DoESA. World Contraceptive Use, 2011. Retrieved 1 May 2013 from at http://www. un. org/esa/popula tion/publications/contraceptive2011/ contraceptive2011. htm.
2. Canning D, Schultz TP. The economic consequences of reproductive health and family planning. Lancet 2012; 380:165-171.
3. Winikoff B, Sullivan M. Assessing the role of family planning in reducing maternalmortality. Stud FamPlann 1987; 18:128-143.
4. Plummer FA, Simonsen JN, Cameron DW, Ndinya-Achola JO, Kreiss JK, Gakinya MN, et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis 1991; 163:233-239.
5. Ungchusak K, Rehle T, Thammapornpilap P, Spiegelman D, Brinkmann U, Siraprapasiri T. Determinants of HIV infection among female commercial sex workers in northeastern Thailand: results from a longitudinal study. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:500-507.
6. Martin HL Jr, Nyange PM, Richardson BA, Lavreys L, Mandaliya K, Jackson DJ, et al. Hormonal contraception, sexually transmitted diseases, and risk of heterosexual transmission of human immunodeficiency virus type 1. J Infect Dis 1998; 178:1053-1059.
7. Marx PA, Spira AI, Gettie A, Dailey PJ, Veazey RS, Lackner AA, et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med 1996; 2:1084-1089.
8. Smith SM, Baskin GB, Marx PA. Estrogen protects against vaginal transmission of simian immunodeficiency virus. J Infect Dis 2000; 182:708-715.
9. Ghanem KG, Shah N, Klein RS, Mayer KH, Sobel JD, Warren DL, et al. Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis 2005; 191:358-366.
10. Morrison CS, Nanda K. Hormonal contraception and HIV: an unanswered question. Lancet Infect Dis 2012; 12:2-3.
11. Sinei SK, Fortney JA, Kigondu CS, Feldblum PJ, Kuyoh M, Allen MY, et al. Contraceptive use and HIV infection in Kenyan family planning clinic attenders. Int J STD AIDS 1996; 7:65-70.
12. Kleinschmidt I, Rees H, Delany S, Smith D, Dinat N, Nkala B, et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Contraception 2007; 75:461-467.
13. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, et al. Hormonal contraception and the risk of HIV acquisition. AIDS 2007; 21:85-95.
14. Cushman LF, Romero D, Kalmuss D, Davidson AR, Heartwell S, Rulin M. Condom use among women choosing long-term hormonal contraception. Fam Plann Perspect 1998; 30:240-243.
15. Polis CB, Gray RH, Lutalo T, Nalugoda F, Kagaayi J, Kigozi G, et al. Trends and correlates of hormonal contraceptive use among HIV-infected women in Rakai, Uganda, 1994-2006. Contraception 2011; 83:549-555.
16. WHO. Hormonal contraception and HIV Technical Statement, WHO/RHR/12. 08. Geneva, 16 February 2012.
17. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012; 12:19-26.
18. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002Art. No. : CD003255.
19. Trussell J. Contraceptive failure in the United States. Contraception 2011; 83:397-404.
20. Darroch J, Singh S. Estimating unintended pregnancies averted from couple-years of protection (CYP). Memorandum published by the Guttmacher Institute 2011.
21. Wand H, Ramjee G. The effects of injectable hormonal contraceptives on HIV seroconversion and on sexually transmitted infections. AIDS 2012; 26:375-380.
22. Baeten JM, Benki S, Chohan V, Lavreys L, McClelland RS, Mandaliya K, et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 2007; 21:1771-1777.
23. Morrison CS, Chen PL, Kwok C, Richardson BA, Chipato T, Mugerwa R, et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 2010; 24:1778-1781.
24. Myer L, Denny L, Wright TC, Kuhn L. Prospective study of hormonal contraception and women's risk of HIV infection in South Africa. Int J Epidemiol 2007; 36:166-174.
25. Kapiga SH, Lyamuya EF, Lwihula GK, Hunter DJ. The incidence of HIV infection among women using family planning methods in Dar es Salaam, Tanzania. AIDS 1998; 12:75-84.
26. Bulterys M, Chao A, Habimana P, Dushimimana A, Nawrocki P, Saah A. Incident HIV-1 infection in a cohort of young women in Butare, Rwanda. AIDS 1994; 8:1585-1591.
27. Reid SE, Dai JY, Wang J, Sichalwe BN, Akpomiemie G, Cowan FM, et al. Pregnancy, contraceptive use, and HIV acquisition in HPTN 039: relevance for HIV prevention trials among African women. J Acquir Immune Defic Syndr 2010; 53:606-613.
28. Watson-Jones D, Baisley K, Weiss HA, Tanton C, Changalucha J, Everett D, et al. Risk factors for HIV incidence in women participating in an HSV suppressive treatment trial in Tanzania. AIDS 2009; 23:415-422.
29. Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, et al. Hormonal contraception and the risk of HIV acquisition among women in South Africa. AIDS 2012; 26:497-504.
30. Kiddugavu M, Makumbi F, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, et al. Hormonal contraceptive use and HIV-1 infection in a population-based cohort in Rakai, Uganda. AIDS 2003; 17:233-240.
31. McCoy SI, Zheng W, Montgomery ET, Blanchard K, van der Straten A, de Bruyn G, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. AIDS 2013; 27:1001-1009.
32. Feldblum PJ, Lie CC, Weaver MA, Van Damme L, Halpern V, Adeiga A, et al. Baseline factors associated with incident HIV and STI in four microbicide trials. Sex Transm Dis 2010; 37:594-601.
33. Ngure K, Heffron R, Mugo NR, Celum C, Cohen CR, Odoyo J, et al. Contraceptive method and pregnancy incidence among women in HIV-1-serodiscordant partnerships. AIDS 2012; 26:513-518.
34. Steiner MJ, Kwok C, Dominik R, Byamugisha JK, Chipato T, Magwali T, et al. Pregnancy risk among oral contraceptive pill, injectable contraceptive, and condom users in Uganda, zimbabwe, and Thailand. Obstet Gynecol 2007; 110:1003-1009.
35. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. Lancet Infect Dis 2013; 13:797-808.
36. Minnis AM, Steiner MJ, Gallo MF, Warner L, Hobbs MM, van der Straten A, et al. Biomarker validation of reports of recent sexual activity: results of a randomized controlled study in Zimbabwe. Am J Epidemiol 2009; 170:918-924.
37. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet 2007; 370:251-261.
38. Marrazzo J. Preexposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). In Conference on Retroviruses and Opportunistic Infections. Atlanta, USA; 2013 [Abstract #26LB].
39. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411-422.
40. Gallo MF, Warner L, Jamieson DJ, Steiner MJ. Do women using long-acting reversible contraception reduce condom use? A novel study design incorporating semen biomarkers. Infect Dis Obstet Gynecol 2011; 2011:Article ID107140.
41. Spiegelman D, McDermott A, Rosner B. Regression calibration method for correcting measurement-error bias in nutritional epidemiology. Am J Clin Nutr 1997; 65:1179S-1186S.
42. Cole SR, Chu H, Greenland S. Multiple-imputation for measurement-error correction. Int J Epidemiol 2006; 35: 1074-1081.
43. Ghanem KG, Hutton HE, Zenilman JM, Zimba R, Erbelding EJ. Audio computer assisted self interview and face to face interview modes in assessing response bias among STD clinic patients. Sex Transm Infect 2005; 81:421-425.
44. Gregson S, Zhuwau T, Ndlovu J, Nyamukapa CA. Methods to reduce social desirability bias in sex surveys in low-development settings: experience in Zimbabwe. Sex Transm Dis 2002; 29:568-575.
45. Hensel DJ, Fortenberry JD, Harezlak J, Craig D. The feasibility of cell phone based electronic diaries for STI/HIV research. BMC Med Res Methodol 2012; 12:75.
46. Jain AK. Hormonal contraception and HIV acquisition risk: implications for individual users and public policies. Contraception 2012; 86:645-652.
47. Rodriguez MI, Reeves MF, Caughey AB. Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: a decision analysis. BJOG 2012; 119:1067-1073.
48. Butler AR, Smith JA, Polis CB, Gregson S, Stanton D, Hallett TB. Modelling the global competing risks of a potential interaction between injectable hormonal contraception and HIV risk. AIDS 2013; 27:105-113.